Molecular targets for the treatment of pancreatic cancer: Clinical and experimental studies

World Journal of Gastroenterology

Volumn 22, Issue 2, 2016, Pages 776-789

  Matsuoka, Tasuku ^a   Yashiro, Masakazu ^a  

^a OSAKA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Cancer stem cell; Microenvironment; Pancreatic cancer; Targeted therapy; Tyrosine kinase inhibitors

Indexed keywords

4 [BIS(2 CHLOROETHYL)OXIDOAMINO]PHENYLALANINE; EPIDERMAL GROWTH FACTOR RECEPTOR; GEMCITABINE; MAMMALIAN TARGET OF RAPAMYCIN; MASITINIB; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; NINTEDANIB; NOTCH RECEPTOR; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; PROTEIN KINASE P60; RAS PROTEIN; SOMATOMEDIN C; TRANSFORMING GROWTH FACTOR BETA; ANTINEOPLASTIC AGENT; TUMOR MARKER;

ANGIOGENESIS; ANTIANGIOGENIC THERAPY; APOPTOSIS; CANCER MORTALITY; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER STEM CELL; CANCER SURVIVAL; CELL PROLIFERATION; GENE MUTATION; MOLECULAR PATHOLOGY; MOLECULARLY TARGETED THERAPY; PANCREAS CANCER; PANCREATIC CANCER CELL LINE; REVIEW; TUMOR GROWTH; WNT SIGNALING PATHWAY; ANIMAL; ANTAGONISTS AND INHIBITORS; DRUG EFFECTS; GENE EXPRESSION REGULATION; GENETIC PREDISPOSITION; GENETICS; HUMAN; METABOLISM; MOLECULAR DIAGNOSIS; MORTALITY; MUTATION; PANCREATIC NEOPLASMS; PATIENT SELECTION; PERSONALIZED MEDICINE; PHENOTYPE; SIGNAL TRANSDUCTION; TUMOR MICROENVIRONMENT;

ANIMALS; ANTINEOPLASTIC AGENTS; BIOMARKERS, TUMOR; GENE EXPRESSION REGULATION, NEOPLASTIC; GENETIC PREDISPOSITION TO DISEASE; HUMANS; MOLECULAR DIAGNOSTIC TECHNIQUES; MOLECULAR TARGETED THERAPY; MUTATION; NEOPLASTIC STEM CELLS; PANCREATIC NEOPLASMS; PATIENT SELECTION; PHENOTYPE; PRECISION MEDICINE; SIGNAL TRANSDUCTION; TUMOR MICROENVIRONMENT;

EID: 84954451703     PISSN: 10079327     EISSN: 22192840     Source Type: Journal    
DOI: 10.3748/wjg.v22.i2.776     Document Type: Review

References (102)

1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J Clin 2012; 62: 10-29 [PMID: 22237781 DOI: 10.3322/caac.20138]
2. Oettle H, Post S, Neuhaus P, Gellert K, Langrehr J, Ridwelski K, Schramm H, Fahlke J, Zuelke C, Burkart C, Gutberlet K, Kettner E, Schmalenberg H, Weigang-Koehler K, Bechstein WO, Niedergethmann M, Schmidt-Wolf I, Roll L, Doerken B, Riess H. Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer: a randomized controlled trial. JAMA 2007; 297: 267-277 [PMID: 17227978 DOI: 10.1001/jama.297.3.267]
3. Borazanci E, Vo n Hoff DD. Nab-paclitaxel and gemcitabine for the treatment of patients with metastatic pancreatic cancer. Expert Rev Gastroenterol Hepatol 2014; 8: 739-747 [PMID: 24882381 DOI: 10.1586/17474124.2014.925799]
4. Thota R, Pauff JM, Berlin JD. Treatment of metastatic pancreatic adenocarcinoma: a review. Oncology (Williston Park) 2014; 28: 70-74 [PMID: 24683721]
5. Jones S, Zhang X, Parsons DW, Lin JC, Leary RJ, Angenendt P, Mankoo P, Carter H, Kamiyama H, Jimeno A, Hong SM, Fu B, Lin MT, Calhoun ES, Kamiyama M, Walter K, Nikolskaya T, Nikolsky Y, Hartigan J, Smith DR, Hidalgo M, Leach SD, Klein AP, Jaffee EM, Goggins M, Maitra A, Iacobuzio-Donahue C, Eshleman JR, Kern SE, Hruban RH, Karchin R, Papadopoulos N, Parmigiani G, Vogelstein B, Velculescu VE, Kinzler KW. Core signaling pathways in human pancreatic cancers revealed by global genomic analyses. Science 2008; 321: 1801-1806 [PMID: 18772397]
6. Rozenblum E, Schutte M, Goggins M, Hahn SA, Panzer S, Zahurak M, Goodman SN, Sohn TA, Hruban RH, Yeo CJ, Kern SE. Tumor-suppressive pathways in pancreatic carcinoma. Cancer Res 1997; 57: 1731-1734 [PMID: 9135016]
7. Yashiro M, Carethers JM, Laghi L, Saito K, Slezak P, Jaramillo E, Rubio C, Koizumi K, Hirakawa K, Boland CR. Genetic pathways in the evolution of morphologically distinct colorectal neoplasms. Cancer Res 2001; 61: 2676-2683 [PMID: 11289147]
8. Moskaluk CA, Hruban RH, Kern SE. p16 and K-ras gene mutations in the intraductal precursors of human pancreatic adenocarcinoma. Cancer Res 1997; 57: 2140-2143 [PMID: 9187111]
9. Hruban RH, van Mansfeld AD, Offerhaus GJ, van Weering DH, Allison DC, Goodman SN, Kensler TW, Bose KK, Cameron JL, Bos JL. K-ras oncogene activation in adenocarcinoma of the human pancreas. A study of 82 carcinomas using a combination of mutant-enriched polymerase chain reaction analysis and allele-specific oligonucleotide hybridization. Am J Pathol 1993; 143: 545-554 [PMID: 8342602]
10. Schutte M, Hruban RH, Geradts J, Maynard R, Hilgers W, Rabindran SK, Moskaluk CA, Hahn SA, Schwarte-Waldhoff I, Schmiegel W, Baylin SB, Kern SE, Herman JG. Abrogation of the Rb/p16 tumor-suppressive pathway in virtually all pancreatic carcinomas. Cancer Res 1997; 57: 3126-3130 [PMID: 9242437]
11. Muller PA, Vousden KH. p53 mutations in cancer. Nat Cell Biol 2013; 15: 2-8 [PMID: 23263379 DOI: 10.1038/ncb2641]
12. Iacobuzio-Donahue CA, Song J, Parmiagiani G, Yeo CJ, Hruban RH, Kern SE. Missense mutations of MADH4: characterization of the mutational hot spot and functional consequences in human tumors. Clin Cancer Res 2004; 10: 1597-1604 [PMID: 15014009 DOI: 10.1158/1078-0432.CCR-1121-3]
13. Blackford A, Serrano OK, Wolfgang CL, Parmigiani G, Jones S, Zhang X, Parsons DW, Lin JC, Leary RJ, Eshleman JR, Goggins M, Jaffee EM, Iacobuzio-Donahue CA, Maitra A, Cameron JL, Olino K, Schulick R, Winter J, Herman JM, Laheru D, Klein AP, Vogelstein B, Kinzler KW, Velculescu VE, Hruban RH. SMAD4 gene mutations are associated with poor prognosis in pancreatic cancer. Clin Cancer Res 2009; 15: 4674-4679 [PMID: 19584151 DOI: 10.1158/1078-0432.CCR-09-0227]
14. Hezel AF, Kimmelman AC, Stanger BZ, Bardeesy N, Depinho RA. Genetics and biology of pancreatic ductal adenocarcinoma. Genes Dev 2006; 20: 1218-1249 [PMID: 16702400 DOI: 10.1101/gad.1415606]
15. Calhoun ES, Jones JB, Ashfaq R, Adsay V, Baker SJ, Valentine V, Hempen PM, Hilgers W, Yeo CJ, Hruban RH, Kern SE. BRAF and FBXW7 (CDC4, FBW7, AGO, SEL10) mutations in distinct subsets of pancreatic cancer: potential therapeutic targets. Am J Pathol 2003; 163: 1255-1260 [PMID: 14507635 DOI: 10.1016/S0002-9440(10)63485-2]
16. Hingorani SR, Petricoin EF, Maitra A, Rajapakse V, King C, Jacobetz MA, Ross S, Conrads TP, Veenstra TD, Hitt BA, Kawaguchi Y, Johann D, Liotta LA, Crawford HC, Putt ME, Jacks T, Wright CV, Hruban RH, Lowy AM, Tuveson DA. Preinvasive and invasive ductal pancreatic cancer and its early detection in the mouse. Cancer Cell 2003; 4: 437-450 [PMID: 14706336 DOI: 10.1016/S1535-6108(03)00309-X]
17. Ardito CM, Grüner BM, Takeuchi KK, Lubeseder-Martellato C, Teichmann N, Mazur PK, Delgiorno KE, Carpenter ES, Halbrook CJ, Hall JC, Pal D, Briel T, Herner A, Trajkovic-Arsic M, Sipos B, Liou GY, Storz P, Murray NR, Threadgill DW, Sibilia M, Washington MK, Wilson CL, Schmid RM, Raines EW, Crawford HC, Siveke JT. EGF receptor is required for KRAS-induced pancreatic tumorigenesis. Cancer Cell 2012; 22: 304-317 [PMID: 22975374 DOI: 10.1016/j.ccr.2012.07.024]
18. Collins MA, Bednar F, Zhang Y, Brisset JC, Galbán S, Galbán CJ, Rakshit S, Flannagan KS, Adsay NV, Pasca di Magliano M. Oncogenic Kras is required for both the initiation and maintenance of pancreatic cancer in mice. J Clin Invest 2012; 122: 639-653 [PMID: 22232209 DOI: 10.1172/JCI59227]
19. Cantley LC. The phosphoinositide 3-kinase pathway. Science 2002; 296: 1655-1657 [PMID: 12040186]
20. Altomare DA, Tanno S, De Rienzo A, Klein-Szanto AJ, Tanno S, Skele KL, Hoffman JP, Testa JR. Frequent activation of AKT2 kinase in human pancreatic carcinomas. J Cell Biochem 2002; 87: 470-476 [PMID: 14735903 DOI: 10.1002/jcb.10287]
21. Hirakawa T, Yashiro M, Murata A, Hirata K, Kimura K, Amano R, Yamada N, Nakata B, Hirakawa K. IGF-1 receptor and IGF binding protein-3 might predict prognosis of patients with resectable pancreatic cancer. BMC Cancer 2013; 13: 392 [PMID: 23962053 DOI: 10.1186/1471-2407-13-392]
22. Neesse A, Michl P, Frese KK, Feig C, Cook N, Jacobetz MA, Lolkema MP, Buchholz M, Olive KP, Gress TM, Tuveson DA. Stromal biology and therapy in pancreatic cancer. Gut 2011; 60: 861-868 [PMID: 20966025 DOI: 10.1136/gut.2010.226092]
23. Whipple C, Korc M. Targeting angiogenesis in pancreatic cancer: rationale and pitfalls. Langenbecks Arch Surg 2008; 393: 901-910 [PMID: 18210149]
24. Koch S, Claesson-Welsh L. Signal transduction by vascular endothelial growth factor receptors. Cold Spring Harb Perspect Med 2012; 2: a006502 [PMID: 22762016 DOI: 10.1101/cshperspect. a006502]
25. Seo Y, Baba H, Fukuda T, Takashima M, Sugimachi K. High expression of vascular endothelial growth factor is associated with liver metastasis and a poor prognosis for patients with ductal pancreatic adenocarcinoma. Cancer 2000; 88: 2239-2245 [PMID: 10820344]
26. Kindler HL, Niedzwiecki D, Hollis D, Sutherland S, Schrag D, Hurwitz H, Innocenti F, Mulcahy MF, O'Reilly E, Wozniak TF, Picus J, Bhargava P, Mayer RJ, Schilsky RL, Goldberg RM. Gemcitabine plus bevacizumab compared with gemcitabine plus placebo in patients with advanced pancreatic cancer: phase III trial of the Cancer and Leukemia Group B (CALGB 80303). J Clin Oncol 2010; 28: 3617-3622 [PMID: 20606091 DOI: 10.1200/JCO.2010.28.1386]
27. Cardin DB, Goff L, Li CI, Shyr Y, Winkler C, DeVore R, Schlabach L, Holloway M, McClanahan P, Meyer K, Grigorieva J, Berlin J, Chan E. Phase II trial of sorafenib and erlotinib in advanced pancreatic cancer. Cancer Med 2014; 3: 572-579 [PMID: 24574334 DOI: 10.1002/cam4.208]
28. Saif MW. Pancreatic cancer: Sorafenib: no effect on efficacy of chemotherapy in pancreatic cancer. Nat Rev Gastroenterol Hepatol 2014; 11: 8-9 [PMID: 24322903]
29. Ioka T, Okusaka T, Ohkawa S, Boku N, Sawaki A, Fujii Y, Kamei Y, Takahashi S, Namazu K, Umeyama Y, Bycott P, Furuse J. Effcacy and safety of axitinib in combination with gemcitabine in advanced pancreatic cancer: subgroup analyses by region, including Japan, from the global randomized Phase III trial. Jpn J Clin Oncol 2015; 45: 439-448 [PMID: 25647781 DOI: 10.1093/jjco/hyv011]
30. Kataoka Y, Mukohara T, Tomioka H, Funakoshi Y, Kiyota N, Fujiwara Y, Yashiro M, Hirakawa K, Hirai M, Minami H. Foretinib (GSK1363089), a multi-kinase inhibitor of MET and VEGFRs, inhibits growth of gastric cancer cell lines by blocking inter-receptor tyrosine kinase networks. Invest New Drugs 2012; 30: 1352-1360 [PMID: 21655918 DOI: 10.1007/s10637-011-9699-0]
31. Kiehne K, Herzig KH, Fölsch UR. c-met expression in pancreatic cancer and effects of hepatocyte growth factor on pancreatic cancer cell growth. Pancreas 1997; 15: 35-40 [PMID: 9211490 DOI: 10.10 97/00006676-199707000-00005]
32. Chen HM, Tsai CH, Hung WC. Foretinib inhibits angiogenesis, lymphangiogenesis and tumor growth of pancreatic cancer in vivo by decreasing VEGFR-2/3 and TIE-2 signaling. Oncotarget 2015; 6: 14940-14952 [PMID: 25909285 DOI: 10.18632/oncotarget.3613]
33. Voldborg BR, Damstrup L, Spang-Thomsen M, Poulsen HS. Epidermal growth factor receptor (EGFR) and EGFR mutations, function and possible role in clinical trials. Ann Oncol 1997; 8: 1197-1206 [PMID: 9496384 DOI: 10.1023/A:1008209720526]
34. Tobita K, Kijima H, Dowaki S, Kashiwagi H, Ohtani Y, Oida Y, Yamazaki H, Nakamura M, Ueyama Y, Tanaka M, Inokuchi S, Makuuchi H. Epidermal growth factor receptor expression in human pancreatic cancer: Signifcance for liver metastasis. Int J Mol Med 2003; 11: 305-309 [PMID: 12579331 DOI: 10.3892/ijmm.11.3.305]
35. Yamanaka Y, Friess H, Kobrin MS, Buchler M, Beger HG, Korc M. Coexpression of epidermal growth factor receptor and ligands in human pancreatic cancer is associated with enhanced tumor aggressiveness. Anticancer Res 1993; 13: 565-569 [PMID: 8317885]
36. Philip PA, Benedetti J, Corless CL, Wong R, O'Reilly EM, Flynn PJ, Rowland KM, Atkins JN, Mirtsching BC, Rivkin SE, Khorana AA, Goldman B, Fenoglio-Preiser CM, Abbruzzese JL, Blanke CD. Phase III study comparing gemcitabine plus cetuximab versus gemcitabine in patients with advanced pancreatic adenocarcinoma: Southwest Oncology Group-directed intergroup trial S0205. J Clin Oncol 2010; 28: 3605-3610 [PMID: 20606093 DOI: 10.1200/JCO.2009.25.7550]
37. Safran H, Iannitti D, Ramanathan R, Schwartz JD, Steinhoff M, Nauman C, Hesketh P, Rathore R, Wolff R, Tantravahi U, Hughes TM, Maia C, Pasquariello T, Goldstein L, King T, Tsai J Y, Kennedy T. Herceptin and gemcitabine for metastatic pancreatic cancers that overexpress HER-2/neu. Cancer Invest 2004; 22: 706-712 [PMID: 15581051 DOI: 10.1081/CNV-200032974]
38. Moore MJ, Goldstein D, Hamm J, Figer A, Hecht JR, Gallinger S, Au HJ, Murawa P, Walde D, Wolff RA, Campos D, Lim R, Ding K, Clark G, Voskoglou-Nomikos T, Ptasynski M, Parulekar W. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 2007; 25: 1960-1966 [PMID: 17452677 DOI: 10.1200/JCO.2006.07.9525]
39. da Cunha Santos G, Dhani N, Tu D, Chin K, Ludkovski O, Kamel-Reid S, Squire J, Parulekar W, Moore MJ, Tsao MS. Molecular predictors of outcome in a phase 3 study of gemcitabine and erlotinib therapy in patients with advanced pancreatic cancer: National Cancer Institute of Canada Clinical Trials Group Study PA.3. Cancer 2010; 116: 5599-5607 [PMID: 20824720 DOI: 10.1002/cncr.25393]
40. Togashi Y, Hayashi H, Nakagawa K, Nishio K. Clinical utility of erlotinib for the treatment of non-small-cell lung cancer in Japanese patients: current evidence. Drug Des Devel Ther 2014; 8: 1037-1046 [PMID: 25114510 DOI: 10.2147/DDDT.S50358]
41. Pollak MN, Schernhammer ES, Hankinson SE. Insulin-like growth factors and neoplasia. Nat Rev Cancer 2004; 4: 505-518 [PMID: 15229476]
42. Urtasun N, Vidal-Pla A, Pérez-Torras S, Mazo A. Human pancreatic cancer stem cells are sensitive to dual inhibition of IGF-IR and ErbB receptors. BMC Cancer 2015; 15: 223 [PMID: 25886138 DOI: 10.1186/s12885-015-1249-2]
43. De Luca A, Maiello MR, D'Alessio A, Pergameno M, Normanno N. The RAS/RAF/MEK/ERK and the PI3K/AKT signalling pathways: role in cancer pathogenesis and implications for therapeutic approaches. Expert Opin Ther Targets 2012; 16 Suppl 2: S17-S27 [PMID: 22443084 DOI: 10.1517/14728222.2011.639361]
44. Willems L, Tamburini J, Chapuis N, Lacombe C, Mayeux P, Bouscary D. PI3K and mTOR signaling pathways in cancer: new data on targeted therapies. Curr Oncol Rep 2012; 14: 129-138 [PMID: 22350330 DOI: 10.1007/s11912-012-0227-y]
45. Schlieman MG, Fahy BN, Ramsamooj R, Beckett L, Bold RJ. Incidence, mechanism and prognostic value of activated AKT in pancreas cancer. Br J Cancer 2003; 89: 2110-2115 [PMID: 14647146 DOI: 10.1038/sj.bjc.6601396]
46. Asano T, Yao Y, Zhu J, Li D, Abbruzzese JL, Reddy SA. The PI 3-kinase/Akt signaling pathway is activated due to aberrant Pten expression and targets transcription factors NF-kappaB and c-Myc in pancreatic cancer cells. Oncogene 2004; 23: 8571-8580 [PMID: 15467756 DOI: 10.1038/sj.onc.1207902]
47. Matsuzaki T, Yashiro M, Kaizaki R, Yasuda K, Doi Y, Sawada T, Ohira M, Hirakawa K. Synergistic antiproliferative effect of mTOR inhibitors in combination with 5-fluorouracil in scirrhous gastric cancer. Cancer Sci 2009; 100: 2402-2410 [PMID: 19764996 DOI: 10.1111/j.1349-7006.2009.01315.x]
48. Kordes S, Klümpen HJ, Weterman MJ, Schellens JH, Richel DJ, Wilmink JW. Phase II study of capecitabine and the oral mTOR inhibitor everolimus in patients with advanced pancreatic cancer. Cancer Chemother Pharmacol 2015; 75: 1135-1141 [PMID: 25822310 DOI: 10.1007/s00280-015-2730-y]
49. Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, de Oliveira AC, Santoro A, Raoul JL, Forner A, Schwartz M, Porta C, Zeuzem S, Bolondi L, Greten TF, Galle PR, Seitz JF, Borbath I, Häussinger D, Giannaris T, Shan M, Moscovici M, Voliotis D, Bruix J. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008; 359: 378-390 [PMID: 18650514 DOI: 10.1056/NEJMoa0708857]
50. Thomas SM, Brugge JS. Cellular functions regulated by Src family kinases. Annu Rev Cell Dev Biol 1997; 13: 513-609 [PMID: 9442882 DOI: 10.1146/annurev.cellbio.13.1.513]
51. Jatiani SS, Baker SJ, Silverman LR, Reddy EP. Jak/STAT pathways in cytokine signaling and myeloproliferative disorders: approaches for targeted therapies. Genes Cancer 2010; 1: 979-993 [PMID: 21442038 DOI: 10.1177/1947601910397187]
52. Seidel HM, Lamb P, Rosen J. Pharmaceutical intervention in the JAK/STAT signaling pathway. Oncogene 2000; 19: 2645-2656 [PMID: 10851064 DOI: 10.1038/sj.onc.1203550]
53. Müller S, Raulefs S, Bruns P, Afonso-Grunz F, Plötner A, Thermann R, Jäger C, Schlitter AM, Kong B, Regel I, Roth WK, Rotter B, Hoffmeier K, Kahl G, Koch I, Theis FJ, Kleeff J, Winter P, Michalski CW. Next-generation sequencing reveals novel differentially regulated mRNAs, lncRNAs, miRNAs, sdRNAs and a piRNA in pancreatic cancer. Mol Cancer 2015; 14: 94 [PMID: 25910082 DOI: 10.1186/s12943-015-0358-5]
54. Lili LN, Matyunina LV, Walker LD, Daneker GW, McDonald JF. Evidence for the importance of personalized molecular profling in pancreatic cancer. Pancreas 2014; 43: 198-211 [PMID: 24518497 DOI: 10.1097/MPA.0000000000000020]
55. Tanase CP, Neagu AI, Necula LG, Mambet C, Enciu AM, Calenic B, Cruceru ML, Albulescu R. Cancer stem cells: involvement in pancreatic cancer pathogenesis and perspectives on cancer therapeutics. World J Gastroenterol 2014; 20: 10790-10801 [PMID: 25152582 DOI: 10.3748/wjg.v20.i31.10790]
56. Rao CV, Mohammed A. New insights into pancreatic cancer stem cells. World J Stem Cells 2015; 7: 547-555 [PMID: 25914762 DOI: 10.4252/wjsc.v7.i3.547]
57. Castellanos JA, Merchant NB, Nagathihalli NS. Emerging targets in pancreatic cancer: epithelial-mesenchymal transition and cancer stem cells. Onco Targets Ther 2013; 6: 1261-1267 [PMID: 24049451]
58. Leach SD. Epithelial differentiation in pancreatic development and neoplasia: new niches for nestin and Notch. J Clin Gastroenterol 2005; 39: S78-S82 [PMID: 15758664 DOI: 10.1097/01. mcg.0000155547.83901.a3]
59. Avila JL, Kissil JL. Notch signaling in pancreatic cancer: oncogene or tumor suppressor? Trends Mol Med 2013; 19: 320-327 [PMID: 23545339 DOI: 10.1016/j.molmed.2013.03.003]
60. Ristorcelli E, Lombardo D. Targeting Notch signaling in pancreatic cancer. Expert Opin Ther Targets 2010; 14: 541-552 [PMID: 20392166 DOI: 10.1517/14728221003769895]
61. Wang Z, Ahmad A, Li Y, Azmi AS, Miele L, Sarkar FH. Targeting notch to eradicate pancreatic cancer stem cells for cancer therapy. Anticancer Res 2011; 31: 1105-1113 [PMID: 21508353]
62. Chen JK, Taipale J, Young KE, Maiti T, Beachy PA. Small molecule modulation of Smoothened activity. Proc Natl Acad Sci USA 2002; 99: 14071-14076 [PMID: 12391318 DOI: 10.1073/pnas.182542899]
63. Thayer SP, di Magliano MP, Heiser PW, Nielsen CM, Roberts DJ, Lauwers GY, Qi YP, Gysin S, Fernández-del Castillo C, Yajnik V, Antoniu B, McMahon M, Warshaw AL, Hebrok M. Hedgehog is an early and late mediator of pancreatic cancer tumorigenesis. Nature 2003; 425: 851-856 [PMID: 14520413 DOI: 10.1038/nature02009]
64. Pasca di Magliano M, Sekine S, Ermilov A, Ferris J, Dlugosz AA, Hebrok M. Hedgehog/Ras interactions regulate early stages of pancreatic cancer. Genes Dev 2006; 20: 3161-3173 [PMID: 17114586 DOI: 10.1101/gad.1470806]
65. Bailey JM, Swanson BJ, Hamada T, Eggers JP, Singh PK, Caffery T, Ouellette MM, Hollingsworth MA. Sonic hedgehog promotes desmoplasia in pancreatic cancer. Clin Cancer Res 2008; 14: 5995-6004 [PMID: 18829478 DOI: 10.1158/1078-0432. CCR-08-0291]
66. Tanaka S. Cancer stem cells as therapeutic targets of hepato-biliary-pancreatic cancers. J Hepatobiliary Pancreat Sci 2015; 22: 531-537 [PMID: 25874410 DOI: 10.1002/jhbp.248]
67. Olive KP, Jacobetz MA, Davidson CJ, Gopinathan A, McIntyre D, Honess D, Madhu B, Goldgraben MA, Caldwell ME, Allard D, Frese KK, Denicola G, Feig C, Combs C, Winter SP, Ireland-Zecchini H, Reichelt S, Howat WJ, Chang A, Dhara M, Wang L, Rückert F, Grützmann R, Pilarsky C, Izeradjene K, Hingorani SR, Huang P, Davies SE, Plunkett W, Egorin M, Hruban RH, Whitebread N, McGovern K, Adams J, Iacobuzio-Donahue C, Griffiths J, Tuveson DA. Inhibition of Hedgehog signaling enhances delivery of chemotherapy in a mouse model of pancreatic cancer. Science 2009; 324: 1457-1461 [PMID: 19460966]
68. Kim EJ, Sahai V, Abel EV, Griffth KA, Greenson JK, Takebe N, Khan GN, Blau JL, Craig R, Balis UG, Zalupski MM, Simeone DM. Pilot clinical trial of hedgehog pathway inhibitor GDC-0449 in combination with gemcitabine in patients with metastatic pancreatic adenocarcinoma. Clin Cancer Res 2014; 20: 5937-5945 [PMID: 25278454 DOI: 10.1158/1078-0432. CCR-14-1269]
69. Baarsma HA, Königshoff M, Gosens R. The WNT signaling pathway from ligand secretion to gene transcription: molecular mechanisms and pharmacological targets. Pharmacol Ther 2013; 138: 66-83 [PMID: 23328704 DOI: 10.1016/j.pharmthera.2013.01.0 02]
70. Espada J, Calvo MB, Díaz-Prado S, Medina V. Wnt signalling and cancer stem cells. Clin Transl Oncol 2009; 11: 411-427 [PMID: 19574199 DOI: 10.1007/s12094-009-0380-4]
71. Cui J, Jiang W, Wang S, Wang L, Xie K. Role of Wnt/β-catenin signaling in drug resistance of pancreatic cancer. Curr Pharm Des 2012; 18: 2464-2471 [PMID: 22372504 DOI: 10.2174/13816128112 092464]
72. Fuxe J, Karlsson MC. TGF-β-induced epithelial-mesenchymal transition: a link between cancer and inflammation. Semin Cancer Biol 2012; 22: 455-461 [PMID: 22627188 DOI: 10.1016/j.semcancer.2012.05.004]
73. Oberstein PE, Olive KP. Pancreatic cancer: why is it so hard to treat? Therap Adv Gastroenterol 2013; 6: 321-337 [PMID: 23814611 DOI: 10.1177/1756283X13478680]
74. Yashiro M, Chung YS, Sowa M. Role of orthotopic fbroblasts in the development of scirrhous gastric carcinoma. Jpn J Cancer Res 1994; 85: 883-886 [PMID: 7961114 DOI: 10.1111/j.1349-7006.1994. tb02963.x]
75. Yashiro M, Ikeda K, Tendo M, Ishikawa T, Hirakawa K. Effect of organ-specific fibroblasts on proliferation and differentiation of breast cancer cells. Breast Cancer Res Treat 2005; 90: 307-313 [PMID: 15830145 DOI: 10.1007/s10549-004-5364-z]
76. Rucki AA, Zheng L. Pancreatic cancer stroma: understanding biology leads to new therapeutic strategies. World J Gastroenterol 2014; 20: 2237-2246 [PMID: 24605023 DOI: 10.3748/wjg.v20. i9.2237]
77. Zhou H, Roy S, Cochran E, Zouaoui R, Chu CL, Duffner J, Zhao G, Smith S, Galcheva-Gargova Z, Karlgren J, Dussault N, Kwan RY, Moy E, Barnes M, Long A, Honan C, Qi YW, Shriver Z, Ganguly T, Schultes B, Venkataraman G, Kishimoto TK. M402, a novel heparan sulfate mimetic, targets multiple pathways implicated in tumor progression and metastasis. PLoS One 2011; 6: e21106 [PMID: 21698156 DOI: 10.1371/journal.pone.0021106]
78. Helleday T, Bryant HE, Schultz N. Poly(ADP-ribose) polymerase (PARP-1) in homologous recombination and as a target for cancer therapy. Cell Cycle 2005; 4: 1176-1178 [PMID: 16123586]
79. Bendell J, O'Reilly EM, Middleton MR, Chau I, Hochster H, Fielding A, Burke W, Burris H. Phase I study of olaparib plus gemcitabine in patients with advanced solid tumours and comparison with gemcitabine alone in patients with locally advanced/metastatic pancreatic cancer. Ann Oncol 2015; 26: 804-811 [PMID: 25573533 DOI: 10.1093/annonc/mdu581]
80. Pan Y, Zheng M, Zhong L, Yang J, Zhou S, Qin Y, Xiang R, Chen Y, Yang SY. A preclinical evaluation of SKLB261, a multikinase inhibitor of EGFR/Src/VEGFR2, as a therapeutic agent against pancreatic cancer. Mol Cancer Ther 2015; 14: 407-418 [PMID: 25519702 DOI: 10.1158/1535-7163.MCT-14-0485]
81. Awasthi N, Hinz S, Brekken RA, Schwarz MA, Schwarz RE. Nintedanib, a triple angiokinase inhibitor, enhances cytotoxic therapy response in pancreatic cancer. Cancer Lett 2015; 358: 59-66 [PMID: 25527450 DOI: 10.1016/j.canlet.2014.12.027]
82. Deplanque G, Demarchi M, Hebbar M, Flynn P, Melichar B, Atkins J, Nowara E, Moyé L, Piquemal D, Ritter D, Dubreuil P, Mansfeld CD, Acin Y, Moussy A, Hermine O, Hammel P. A randomized, placebo-controlled phase III trial of masitinib plus gemcitabine in the treatment of advanced pancreatic cancer. Ann Oncol 2015; 26: 1194-1200 [PMID: 25858497 DOI: 10.1093/annonc/mdv133]
83. Shibaji T, Nagao M, Ikeda N, Kanehiro H, Hisanaga M, Ko S, Fukumoto A, Nakajima Y. Prognostic significance of HIF-1 alpha overexpression in human pancreatic cancer. Anticancer Res 2003; 23: 4721-4727 [PMID: 14981919]
84. Zhao T, Ren H, Jia L, Chen J, Xin W, Yan F, Li J, Wang X, Gao S, Qian D, Huang C, Hao J. Inhibition of HIF-1α by PX-478 enhances the anti-tumor effect of gemcitabine by inducing immunogenic cell death in pancreatic ductal adenocarcinoma. Oncotarget 2015; 6: 2250-2262 [PMID: 25544770 DOI: 10.18632/oncotarget.2948]
85. Miyashita K, Nakada M, Shakoori A, Ishigaki Y, Shimasaki T, Motoo Y, Kawakami K, Minamoto T. An emerging strategy for cancer treatment targeting aberrant glycogen synthase kinase 3 beta. Anticancer Agents Med Chem 2009; 9: 1114-1122 [PMID: 19925395 DOI: 10.2174/187152009789734982]
86. Marchand B, Tremblay I, Cagnol S, Boucher MJ. Inhibition of glycogen synthase kinase-3 activity triggers an apoptotic response in pancreatic cancer cells through JNK-dependent mechanisms. Carcinogenesis 2012; 33: 529-537 [PMID: 22201186 DOI: 10.1093/carcin/bgr309]
87. Ma S, Li Q, Pan F. CXCR4 promotes GSK3β expression in pancreatic cancer cells via the Akt pathway. Int J Clin Oncol 2015; 20: 525-530 [PMID: 25145299]
88. Clark KL, Halay ED, Lai E, Burley SK. Co-crystal structure of the HNF-3/fork head DNA-recognition motif resembles histone H5. Nature 1993; 364: 412-420 [PMID: 8332212 DOI: 10.1038/364412a0]
89. Wang Z, Banerjee S, Kong D, Li Y, Sarkar FH. Down-regulation of Forkhead Box M1 transcription factor leads to the inhibition of invasion and angiogenesis of pancreatic cancer cells. Cancer Res 2007; 67: 8293-8300 [PMID: 17804744 DOI: 10.1158/0008-5472. CAN-07-1265]
90. Huang C, Xie D, Cui J, Li Q, Gao Y, Xie K. FOXM1c promotes pancreatic cancer epithelial-to-mesenchymal transition and metastasis via upregulation of expression of the urokinase plasminogen activator system. Clin Cancer Res 2014; 20: 1477-1488 [PMID: 24452790 DOI: 10.1158/1078-0432.CCR-13-2311]
91. Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 2004; 116: 281-297 [PMID: 14744438 DOI: 10.1016/S0092-8674(04)00045-5]
92. Rachagani S, Kumar S, Batra SK. MicroRNA in pancreatic cancer: pathological, diagnostic and therapeutic implications. Cancer Lett 2010; 292: 8-16 [PMID: 20004512 DOI: 10.1016/j.canlet.2009.11.010]
93. Park WG, Yan BM, Schellenberg D, Kim J, Chang DT, Koong A, Patalano C, Van Dam J. EUS-guided gold fducial insertion for image-guided radiation therapy of pancreatic cancer: 50 successful cases without fuoroscopy. Gastrointest Endosc 2010; 71: 513-518 [PMID: 20189509 DOI: 10.1016/j.gie.2009.10.030]
94. Hwang JH, Voortman J, Giovannetti E, Steinberg SM, Leon LG, Kim YT, Funel N, Park JK, Kim MA, Kang GH, Kim SW, Del Chiaro M, Peters GJ, Giaccone G. Identifcation of microRNA-21 as a biomarker for chemoresistance and clinical outcome following adjuvant therapy in resectable pancreatic cancer. PLoS One 2010; 5: e10630 [PMID: 20498843 DOI: 10.1371/journal.pone.0010630]
95. MacKenzie TN, Mujumdar N, Banerjee S, Sangwan V, Sarver A, Vickers S, Subramanian S, Saluja AK. Triptolide induces the expression of miR-142-3p: a negative regulator of heat shock protein 70 and pancreatic cancer cell proliferation. Mol Cancer Ther 2013; 12: 1266-1275 [PMID: 23635652 DOI: 10.1158/1535-7163. MCT-12-1231]
96. Li Y, Vandenboom TG, Wang Z, Kong D, Ali S, Philip PA, Sarkar FH. miR-146a suppresses invasion of pancreatic cancer cells. Cancer Res 2010; 70: 1486-1495 [PMID: 20124483 DOI: 10.1158/0008-5472.CAN-09-2792]
97. Li L, Li Z, Kong X, Xie D, Jia Z, Jiang W, Cui J, Du Y, Wei D, Huang S, Xie K. Down-regulation of microRNA-494 via loss of SMAD4 increases FOXM1 and β-catenin signaling in pancreatic ductal adenocarcinoma cells. Gastroenterology 2014; 147: 485-97. e18 [PMID: 24859161]
98. Kern SE, Shi C, Hruban RH. The complexity of pancreatic ductal cancers and multidimensional strategies for therapeutic targeting. J Pathol 2011; 223: 295-306 [PMID: 21125682 DOI: 10.1002/path.2813]
99. Van Dort ME, Galbán S, Wang H, Sebolt-Leopold J, Whitehead C, Hong H, Rehemtulla A, Ross BD. Dual inhibition of allosteric mitogen-activated protein kinase (MEK) and phosphatidylinositol 3-kinase (PI3K) oncogenic targets with a bifunctional inhibitor. Bioorg Med Chem 2015; 23: 1386-1394 [PMID: 25766633 DOI: 10.1016/j.bmc.2015.02.053]
100. Hu C, Dadon T, Chenna V, Yabuuchi S, Bannerji R, Booher R, Strack P, Azad N, Nelkin BD, Maitra A. Combined Inhibition of Cyclin-Dependent Kinases (Dinaciclib) and AKT (MK-2206) Blocks Pancreatic Tumor Growth and Metastases in Patient-Derived Xenograft Models. Mol Cancer Ther 2015; 14: 1532-1539 [PMID: 25931518 DOI: 10.1158/1535-7163.MCT-15-0028]
101. Lindberg JM, Newhook TE, Adair SJ, Walters DM, Kim AJ, Stelow EB, Parsons JT, Bauer TW. Co-treatment with panitumumab and trastuzumab augments response to the MEK inhibitor trametinib in a patient-derived xenograft model of pancreatic cancer. Neoplasia 2014; 16: 562-571 [PMID: 25117978 DOI: 10.1016/j.neo.2014.06.004]
102. Tang SC, Chen YC. Novel therapeutic targets for pancreatic cancer. World J Gastroenterol 2014; 20: 10825-10844 [PMID: 25152585 DOI: 10.3748/wjg.v20.i31.10825]